Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Adding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on ...

The research team found that not only was RAS(ON) multi-selective inhibition effective in preclinical pancreatic cancer models, but it was even more effective when combined with immunotherapy. Using ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

CTA approval marks Anocca’s transition to a clinical-stage companyFirst-in-human VIDAR-1 trial begins with the deployment of ...

I knew I was kind of a guinea pig, but the only other option was staying at home, and I wasn’t going to make it,” Tim Story ...

RNA vaccines were first developed years ago to target cancers and now they're really starting to show promise.

NEIGHBOURS veteran Ian Smith has given an update on his health after being diagnosed with terminal cancer in December. The ...

Colorectal cancer, most commonly known as colon cancer, has been the third most prevalent cancer worldwide, comprising about ...

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...